XML 44 R32.htm IDEA: XBRL DOCUMENT v3.21.2
Note 7 - Subsequent Events (Details Textual) - Sorrento Therapeutics, Inc. [Member] - Subsequent Event [Member]
Aug. 10, 2021
USD ($)
License Agreement, Up-front Fee Receivable $ 10,000,000
License Agreement, Up-front Fee Receivable, Cash 5,000,000
License Agreement, Up-front Fee Receivable, Shares 5,000,000
License Agreement, Maximum Reimbursements for Preclinical and Clinical Development Costs 4,000,000
License Agreement, Maximum Milestone Payments Receivable $ 33,000,000